Showing 531-540 of 595 results for "".
- Cipher Pharmaceuticals appoints Lynne Bulger as Vice President, Medical Affairshttps://practicaldermatology.com/news/cipher-pharmaceuticals-appoints-lynne-bulger-as-vice-president-medical-affairs/2459022/Cipher Pharmaceuticals Inc. appointed Lynne Bulger as Vice President, Medical and Clinical Affairs to lead the Company's clinical development and medical affairs efforts for current and new pipeline products. Ms. Bulger has 27 years of experience in drug development in the pharmaceuti
- MELA Sciences Appoints Dr. Darrell Rigel as Chief Medical Advisor to Its Board of Directorshttps://practicaldermatology.com/news/20131001-mela_sciences_appoints_dr_darrell_rigel_as_chief_medical_advisor_to_its_board_of_directors/2459445/MELA Sciences, Inc., announced that Darrell S. Rigel, MD, MS, Clinical Professor of Dermatology at New York University, Langone Medical Center, has been appointed Chief Medical Advisor to the Company's Board of Directors. Dr. Rigel is a Clinical Profes
- Tana Poppino to Be Celtic Complexion Sponsorhttps://practicaldermatology.com/news/20130110-tana_poppino_to_be_celtic_complexion_sponsor/2459641/Florida-based skin care company Celtic Complexion announced a sponsorship agreement with professional rodeo barrel racer Tana Poppino. Ms. Poppino, who lives in Big Cabin, OK, is a full-time contestant on the professional rodeo circuit. S
- Nathalie Daste Named LEO Pharma’s New Executive Vice President of Global People and Corporate Affairshttps://practicaldermatology.com/news/nathalie-daste-named-leo-pharmas-new-executive-vice-president-of-global-people-and-corporate-affairs/2461964/Nathalie Daste is LEO Pharma’s new Executive Vice President, Global People and Corporate Affairs, and member of its Global Leadership Team, effective October 1, 2023. In her new role, Ms. Daste will head LEO Pharma’s Global People function as well as Corporate Affa
- DecisionDx-Melanoma Outperforms MSKCC Nomogram in Predicting Sentinel Lymph Node Positivity in Melanomahttps://practicaldermatology.com/news/decisiondx-melanoma-outperforms-mskcc-nomogram-in-predicting-sentinel-lymph-node-positivity-in-melanoma/2462044/Castle Biosciences, Inc.’s DecisionDx-Melanoma outperformed a nomogram developed at the Memorial Sloan Kettering Cancer Center (MSKCC) in predicting the risk of sentinel lymph node (SLN) positivity in patients with cutaneous melanoma (CM), according to a new study in
- Prolactin Receptor Blockade May Promote Hair Growth via Follicular Stem Cell Activationhttps://practicaldermatology.com/news/prolactin-receptor-blockade-may-promote-hair-growth-via-follicular-stem-cell-activation/2485612/Blocking prolactin receptor (PRLR) signaling with the investigational antibody ABS-201 promoted hair follicle growth and stem cell activation in human male scalp skin models, according to preclinical data from Jérémy Chéret, PhD, MSc, at the South Beach Symposium
- Skin Cancer Champions Launches Integrated Public, Private Communityhttps://practicaldermatology.com/news/skin-cancer-champions-launches-integrated-public-private-community/2484106/The Skin Cancer Champions organization, led by dermatologists Emily Ruiz, MD, MPH, and Chrysalyne Schmults, MD, MSce, FAAD, announced the official launch of its integrated public and private community at skincancerchampions.org. The public platform expands the group’s reach by offering edu
- ElderDerm Co-Director Suggests Alternatives for 'Senile' in Diagnoseshttps://practicaldermatology.com/news/ElderDerm-Co-Director-Suggests-Alternatives-Senile-Diagnoses/2474689/The word senile can be avoided in discussing dermatologic diseases, Jaya Manjunath, MSIV, asserted at the ElderDerm 2025 Conference in Washington, DC. Manjunath, a medical student and co-director of the conference along with Practical Dermatology editorial board member Adam Friedm
- Analysis: FDA Approvals Highlight Disparities in Oncology Outcomes by Ancestryhttps://practicaldermatology.com/news/analysis-fda-approvals-highlight-disparities-oncology-outcomes-ancestry/2470889/Patients of African ancestry remain underrepresented in eligibility for biomarker-driven precision oncology therapies, according to a new study in JAMA Dermatology. The retrospective analysis of 59,433 patients with solid cancers looked at genetic sequencing data from MSK-IMPACT a
- A Novel Dual-Wavelength, Nd:YAG, Picosecond-domain Laser Safely and Effectively Removes Multicolor Tattooshttps://practicaldermatology.com/news/a-novel-dual-wavelength-ndyag-picosecond-domain-laser-safely-and-effectively-removes-multicolor-tattoos/2458848/Research conducted by Eric F. Bernstein MD, MSc; Kevin T. Schomacker PhD; Lisa D. Basilavecchio RN; Jessica M. Plugis; and Jayant D. Bhawalkar PhD, published in the September 2015 issue of Lasers in Surgery and Medicine (LSM), evaluated 21 tattooed subjects between the ages of 19-55 who